Astragalin
CAS 480-10-4
Astragalin (CAS 480-10-4) is a pharmaceutical compound with 7 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 35798.63636363636 nM | 22 | - |
| - | Potency | 34984.1125 nM | 8 | - |
| - | Ki | 8197.966666666667 nM | 6 | - |
| - | IC50 | 36.94 ug.mL-1 | 5 | - |
| - | AC50 | 14926.333333333334 nM | 3 | - |
| - | EC50 | 58233.333333333336 nM | 3 | - |
| - | MIC | 128 ug.mL-1 | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Astragalin used for in pharmaceutical contexts?
Astragalin (CAS 480-10-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Astragalin?
No adverse-event association or SIDER side-effect rows are rendered for Astragalin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Astragalin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Astragalin with EU status "permitted".
What clinical phase is Astragalin in?
No phase 1-4 clinical development badge is rendered for Astragalin because the matched compound identifier rows do not contain a max-phase value.